Modern topical treatment of psoriasis in diabetic patients
- Autores: Lykova S.G1, Nemchaninova O.B1, Svechnikova E.V.1, Morzhanayeva M.A1
-
Afiliações:
- Novosibirsk State Medical University
- Edição: Volume 27, Nº 4 (2020)
- Páginas: 102-107
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312563
- DOI: https://doi.org/10.18565/pharmateca.2020.4.102-107
- ID: 312563
Citar
Texto integral
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Palavras-chave
Texto integral
Sobre autores
S. Lykova
Novosibirsk State Medical UniversityDepartment of Dermatovenereology and Cosmetology
O. Nemchaninova
Novosibirsk State Medical UniversityDepartment of Dermatovenereology and Cosmetology
Elena Svechnikova
Novosibirsk State Medical University
Email: elene-elene@bk.ru
Dr. Sci. (Med.), Associate Professor, Professor at the Department of Dermatovenerology and Cosmetology
M. Morzhanayeva
Novosibirsk State Medical UniversityDepartment of Dermatovenereology and Cosmetology
Bibliografia
- Данилов С.И., Нечаева О.С., Пирятинская А.Б. Медико-социальные факторы риска обострений хронических дерматозов. Российский журнал кожно-венерологических болезней. 2006;1:60-6.
- Walter J.F., Stoughton R.B., DeQuoy PR. Suppression of epidermal proliferation by ultraviolet light, coal tar and anthralin. Br J. Dermatol. 1978;99:89-96. Doi: 10.1111/ j.1365-2133.1978.tb01965.x.
- Gerritsen M.J., Rulo H.F., Van Vlijmen-Willems I., et al. Topical treatment of psoriatic plaques with 1,25-dihydroxyvitamin D3: a cell biologic study. Br J. Dermatol. 1993;128:666-73. doi: 10.1111/j.1365-2133.1993.tb00263.x.
- Reichtrath J., Perez A., Muller S.M., et al. Topical calcitriol (1,25-dihydroxyvitamin D3) treatment of psoriasis: an immunohistological evaluation. Acta Derm Venereol. (Stockh).1997;77:268-72. doi: 10.2340/00015555 772 682 72
- Lebwohl M., Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol. 2001;45:487-502. Doi: 10.1067/ mjd.2001.117046
- Duvic M., Nagpal S., Asano A.T., Chandraratna R.A. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol. 1997;37:18-24
- Weinstein G.D., Krueger G.G., Lowe N.J., et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol. 1997;37:85-92. Doi: 10.1016/ s0190-9622(97)70216-0.
- Hengge U.R., Ruzicka T., Schwartz R.A., Cork M.J. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1-15. doi: 10.1016/j.jaad.2005.01.010
- Dahl M.G.C. Hazards of topical steroid therapy. Adv Drug React Bull. 1985;115:428-31.
- Ammar N.M., Rao B., Schwartz R.A., Janniger C.K. Adolescent striae. Cutis. 2000;65:69-70.
- Lebwohl M.G., Tan M.H., Meador S.L., Singer G. Limited application of fluticasone propionate ointment 0.005% in patients with psoriasis of the face and intertriginous areas. J Am Acad Dermatol. 2001;44:77-82. Doi: 10.1067/ mjd.2001.110046.
- Ramsay B., Lawrence C.M., Bruce J.M., Shuster S. The effects of triethanolamine application on anthralin-induced inflammation and therapeutic effect in psoriasis. J Am Acad Dermatol. 1990;23:73-6. doi: 10.1016/0190-9622(90)70189-o.
- Runne U., Kunze J. Short duration ("minutes") therapy with dithranol for psoriasis: a new outpatient regimen. Br J Dermatol. 1982;106:135-39. doi: 10.1111/j.1365-2133.1982.tb00922.x.
- Gelmetti C. Therapeutic moisturizers as adjuvant therapy for psoriasis patients. Am J Clin Dermatol. 2009;10:7-12. doi: 10.2165/0128071-200910001-00002.
- Witman P.M. Topical therapies for localized psoriasis. Mayo Clin Proc. 2001;76:943-49. doi: 10.4065/76.9.943.
- Bruner C.R., Feldman S.R., Ventrapragada M., Fleischer A.B. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol On-line J. 2003;9:2.
- Lebwohl M.G., Breneman D.L., Goffe B.S. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J. Am Acad Dermatol. 1998;39:590-96.Doi: 10.1016/ s0190-9622(98)70008-8.
- lebwohl M., Lombardi K., Tan M.H. Duration of improvement of psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0,05% ointment: comparison of maintenance treatments. Int J. Dermatol. 2001;40:64-6. doi: 10.1046/j.1365-4362.2001.01067-7.x.
- Kaidbey K., Kopper S.C., Sefton J., Gibson J.R. A pilot study to determine the effect of tazarotene 0.1% gel on steroid-induced epidermal atrophy. Int J. Dermatol. 2001;40:468-71. doi: 10.1046/j.1365-4362.2001.01234.x.
- Lebwohl M. The role of salicylic acid in the treatment of psoriasis. Int J. Dermatol. 1999;38:16-24. doi: 10.1046/j.1365-4362.1999.00500.x.
- Дмитрук В.С. Опыт применения мази Карталин при ладонно-подошвенной форме псориаза идругих кератодермиях. Бюллетень сибирской медицины. 2011;1:112-16
- Солятова В.М. Оптимизация терапии псориаза с учетом изменений липидной плен ки в окологодовом ритме. Дисс. канд. мед. наук. Новосибирск, 2009